- 1 The machine learning algorithm identified COL7A1 as a diagnostic marker for
- 2 LUSC and HNSC
- 3 Chenyu Wang¹; Yongxin Ma²; Jiaojiao Qi^{2, 3*}; Xianglai Jiang^{4*}
- ⁴ ¹ Xiangya Hospital of Central South University, Changsha, 410008, China
- ⁵ ² Ningxia Medical University, Yinchuan, 750004, China
- ⁶ ³ General Hospital of Ningxia Medical University, 750004, China
- ⁷ ⁴ School of basic medical sciences and life sciences, Hainan Medical University,
- 8 Haikou, 571199, China
- 9 * Correspondence:
- 10 Jiaojiao Qi
- 11 <u>qjjdemyx@163.com</u>
- 12 Xianglai Jiang
- 13 jiangx11997@126.com
- 14 Abstract
- Squamous cell carcinomas (SCCs) comes from different parts, but there may be similar 15 tumorigenic signaling pathways and metabolism, and different squamous cell 16 carcinoma has a similar mutation landscape and squamous differentiation expression. 17 Studying the expression profile of common SCCs is helpful to find biomarkers with 18 diagnostic and prognostic significance for a variety of squamous cell carcinoma. Lung 19 20 squamous cell carcinoma (LUSC), head and neck squamous cell carcinoma (HNSC), and 'squamous cell cancer' in esophageal carcinoma (ESCA) and cervical squamous 21 cell carcinoma and endocervical adenocarcinoma (CESC) in The Cancer Genome Atlas 22 (TCGA) database were used as training sets. The relevant data sets in the Gene 23 24 Expression Omnibus (GEO) database were selected as validation sets. Machine learning algorithms were used to screen out factors with high accuracy in the diagnosis 25 of SCCs as core genes, and explore their effects on patient prognosis and 26 immunotherapy. COL7A1 (Collagen Type VII Alpha 1 Chain) has high accuracy in the 27 diagnosis of LUSC and HCSC, whether in the training set (LUSC AUC: 0.987; HNSC 28 AUC: 0.933) or validation set (LUSC AUC: 1.000; HNSC AUC: 0.967). Moreover, 29 the expression of COL7A1 was significantly correlated with shorter OS and DSS in 30 HNSC and LUSC patients, and was also significantly negatively correlated with IPS in 31 LUSC patients treated with CTLA4 (-) PD1 (+), CTLA4 (+) PD1 (-) and CTLA4 (+) 32 33 PD1 (+). COL7A1 has the potential to be used as a diagnostic and prognostic marker for LUSC and HNSC and to predict the efficacy of LUSC immunotherapy. 34

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 Keywords: machine learning, squamous cell carcinoma, diagnostic biomarker,

36 *COL7A1*

37 Introduction

Squamous cell carcinomas (SCCs) occur in epithelial cells and squamous cells. 38 Common lesions include skin, esophagus, cervix, vagina, bronchus, etc¹⁻⁶. The known 39 causes of squamous cell carcinoma are diverse, including gene mutations, age, 40 ultraviolet and human papillomavirus infection^{3, 7}. SCCs with high incidence mainly 41 include esophageal squamous cell carcinoma (ESCC), head and neck squamous cell 42 carcinoma (HNSC), lung squamous cell carcinoma (LUSC) and cervical squamous cell 43 carcinoma (CSCC). Lung squamous cell carcinoma is derived from bronchial 44 epithelium and belongs to non-small cell lung cancer (NSCLC), and the 5-year survival 45 rate of patients with LUSC is less than 20 %⁸. The diagnosis of LUSC and lung 46 be identified by adenocarcinoma (LUAD) can detecting whether the 47 immunohistochemical staining results of P63, P40 and CK5 / 6 are positive⁹. HNSC is 48 the sixth most common cause of cancer death in the world. Due to the high recurrence 49 and metastasis rate of advanced HNSC, the prognosis of patients with advanced HNSC 50 is still poor even with various treatments such as surgery, radiotherapy and 51 chemotherapy¹⁰. Esophageal squamous cell carcinoma ESCC is the main subtype of 52 esophageal cancer. ESCC is highly heterogeneous, and the 5-year survival rate is about 53 20 %^{11, 12}. CESC is the second most common gynecological cancer; there is still a lack 54 of good biomarkers to detect early CESC, and CESC is often found in the advance 55 stage¹³. SCCs come from different parts, but may have similar tumorigenic signaling 56 pathways and metabolism, and different SCCs have similar mutation landscapes (such 57 as TP53, SOX2 and TP63) and squamous differentiation expression¹⁴⁻¹⁸. Studying the 58 expression profile of common SCCs is conducive to the discovery of biomarkers with 59 diagnostic and prognostic significance for a variety of squamous cells, to detect SCCs 60 early to improve the therapeutic effect of SCCs patients. 61

Bioinformatics technology provides a new method for the screening of tumor markers. The analysis of high-throughput sequencing data using bioinformatics technology is more conducive to finding genes with diagnostic value. The machine learning algorithm LASSO regression and SVM-RFE were used to identify the core genes with diagnostic potential. The Receiver Operating Characteristic Curve (ROC curve) was drawn and the area under the ROC curve (AUC) was calculated. The core genes with the most diagnostic value were selected as the diagnostic markers of squamous cell carcinoma,

and the possible role of core genes in the development of specific cancers was

70 analyzed¹⁹⁻²¹.

71 Method

72 Collect and process datasets

The RNA-seq and corresponding clinical data of LUSC, HNSC, and SCCs samples in ESCA and CESC in the TCGA database were used as training sets. Similarly, datasets from GEO (GSE9850, GSE19188, GSE23400, GSE30784) were collected and the sva R package was used to perform batch correction for four datasets²²⁻²⁵. The Limma R software package was used to calculate the differential genes between squamous cell carcinoma tissues and adjacent tissues. Differential genes with $|\log FC| > 2$ and p value < 0.05 were selected as validation sets.

80 Machine learning algorithms screen core genes

LASSO regression can use the constructed penalty function to calculate the optimal model and prevent the model from overfitting. The genes formed by the optimal model analyzed by lasso regression were used as the core genes for the diagnosis of squamous cell carcinoma. SVM-RFE is a machine learning algorithm based on Embedded method, which can complete the sorting of feature genes while screening useful feature genes¹⁹⁻ ²¹. The LASSO model was used to screen the core genes with diagnostic value for

squamous cell carcinoma. On this basis, the SVM-RFE algorithm was used to calculate 87 88 the final gene set with diagnostic value. The ROC R software package was used to draw the ROC curve of each gene expression in the core gene set and calculate the area under 89 the ROC curve. Genes with high accuracy in both training set and validation set were 90 selected as diagnostic markers for squamous cell carcinoma. The AUC of the expression 91 92 of diagnostic markers in HNSC, LUSC, CSCC and ESCC was calculated respectively, and cancers with high diagnostic rates were selected to further analyze the possible 93 biological functions of diagnostic markers in these cancers. 94

95 Clinical features and prognosis analysis

96 The expression of core genes in squamous cell carcinoma was selected, and the 97 correlation between the expression of core genes and the patient's age, gender, stage, T 98 staging, N staging, M staging was completed. The data of OS, DSS, DFI and PFI in 99 patients with squamous cell carcinoma were collected and divided into two groups 100 according to the expression of core genes. The correlation between the expression of 101 SCCs core genes and OS, DSS, DFI and PFI was completed.

102 Methylation analysis

103 Methylation is a kind of epigenetic phenomenon and the main form of $epigenetics^{26}$.

- 104 CpG islands are generated by promoter methylation to silence genes, thereby regulating
- 105 gene expression. Methylation does not change DNA sequences, but can change traits
- and pass on to the next generation²⁷. The promoter methylation data of core genes in
- 107 UALCAN website were collected to study the effect of core gene methylation on OS
- 108 in patients with squamous cell carcinoma.

109 Enrichment analysis

- 110 Gene ontology (GO) analysis involves biological processes, molecular functions and
- 111 cellular components. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, as
- a widely used database, includes information on currently known signaling pathways.
- 113 The 'c5.go.v7.4.symbols.gmt 'file and the 'c2.cp.kegg.v7.4.symbols.gmt 'file from the
- 114 Molecular Signatures Database (MSigDB) were downloaded and used to perform
- 115 GSEA-based GO enrichment analysis and KEGG enrichment analysis on differential 116 genes in high and low expression samples of core genes.

117 Analysis of tumor microenvironment and immune cell infiltration

The tumor microenvironment includes the structure, function and metabolism of the 118 tissue where the tumor is located. It is also related to the internal environment of the 119 tumor cells themselves. The tumor microenvironment regulates the occurrence, 120 development and metastasis of the tumor. As a complex and dynamically regulated 121 122 system, tumor microenvironment is composed of tumor cells, immune cells and supporting cells. The Estimate R software package was used to calculate the correlation 123 between the expression of core genes and StromalScore, ImmuneScore and 124 ESTIMATEScore in specific squamous cell carcinomas using wilcox test. The TMIER 125 126 method was used to calculate the correlation between core gene expression and infiltration of B cell, T cell CD4, T cell CD8, Neutrophil, Macrophage and DC. 127

128 Analysis of Immunotherapy

- As an indicator of tumor immunogenicity, immunophenoscore (IPS) can predict the effect of immunotherapy in cancer patients²⁸. Immunotherapy data were obtained from the TCIA database, and the correlation between the expression of core genes and IPS treated with CTLA4 (-) PD1 (-), CTLA4 (-) PD1 (+), CTLA4 (+) PD1 (-) and CTLA4
- 133 (+)
- 134 **Results**

135 **Determination of core genes**

136 The limma package was used to screen the differential genes (227 in total). The results

of lasso regression analysis showed that a total of 37 genes were identified (Fig.1.A). 137 The svm-rfe algorithm showed that a total of ten genes (SPP1, VEGFD, IL33, 138 GPIHBP1, KIF18B, CRNN, HJURP, COL7A1, TMEM132A, CHI3L2) were identified 139 as core genes (Fig.1.B). The AUC results of each gene in SCCs showed that 140 TMEM132A (AUC: 0.944), KIF18B (AUC: 0.975), HJURP (AUC: 0.976) and 141 COL7A1 (AUC: 0.929) had a higher diagnostic rate for squamous cell carcinoma in the 142 training set (TCGA dataset) (Fig.2.A-J). The analysis results in the validation set (GEO 143 dataset) showed that only COL7A1 (AUC: 0.907) had a high diagnostic rate for SCCs, 144 so COL7A1 was selected as the core gene for the diagnosis of squamous cell carcinoma 145 (Fig.3.A-D). The analysis of COL7A1 in different squamous cell carcinomas showed 146 that the AUC of COL7A1 in CESC was 0.968 (Fig.4.A), the AUC in ESCA was 0.537 147 (Fig.4.B), the AUC in HNSC was 0.933 (Fig.4.C) and the AUC in LUSC was 0.987 148 (Fig.4.D) in the TCGA dataset. The AUC of COL7A1 in CESC was 0.648 (Fig.4.E), in 149 150 ESCA was 0.951 (Fig.4.F), in HNSC was 0.967 (Fig.4.G) and in LUSC was 1.000 (Fig.4.H) in GEO dataset. COL7A1 was selected as a diagnostic biomarker for HNSC 151 152 and LUSC for further analysis.

153 Clinical features and prognosis analysis

The results of clinical characteristics analysis showed that there was no significant 154 correlation between the expression of COL7A1 and age, gender, stage, T staging, N 155 156 staging and M staging in LUSC patients and HNSC patients (Fig.5.A-F). The results of 157 KM prognostic analysis showed that the high expression of COL7A1 was significantly positively correlated with shorter OS (Fig.6.A) and DSS (Fig.6.C) in LUSC patients 158 and shorter OS (Fig.6.E) and DSS (Fig.6.G) in HNSC patients. There was no significant 159 difference in DFI (Fig.6.B) and PFI (Fig.6.D) between LUSC patients with high and 160 low expression of COL7A1, and there was no significant difference in DFI (Fig.6.F) 161 and PFI (Fig.6.H) between HNSC patients with high and low expression of COL7A1. 162 **Promoter methylation level** 163

164 The methylation level of COL7A1 in LUSC and HNSC obtained from UCSC xena 165 website showed that COL7A1 had a lower Promoter methylation level in LUSC tumor 166 (Fig.7.A-B).

167 Enrichment analysis

Go enrichment analysis showed that the expression of COL7A1 was positively correlated with the activation of artery development, detection of chemical stimulus, sensory perception of smell, odorant binding and olfactory receptor activity in LUSC

(Fig.8.A). And COL7A1 was positively correlated with the activation of etection of 171 chemical stimulus, muscle cell proliferation, sensory perception of smell, transforming 172 growth factor beta receptor signaling pathway and olfactory receptor activity in HNSC 173 (Fig.8.C). KEGG enrichment analysis showed that the expression of COL7A1 was 174 positively correlated with the activation of olfactory transduction, and negatively 175 correlated with the activation of folate biosynthesis in LUSC (Fig.8.B). The expression 176 of COL7A1 was positively correlated with the activation of olfactory transduction, and 177 negatively correlated with the activation of O glycan biosynthesis, riboflavin 178 metabolism and starch and sucrose metabolism in HNSC (Fig.8.D). 179

180 Tumor microenvironment and immune cell infiltration

The results of tumor microenvironment analysis showed that the StromalScore, 181 ImmuneScore and ESTIMATEScore of LUSC samples in the low expression group of 182 COL7A1 were significantly higher than those in the high expression group of COL7A1 183 (Fig.9.A). There was no significant difference in StromalScore, ImmuneScore and 184 ESTIMATEScore between HNSC samples of COL7A1 low expression group and 185 HNSC samples of COL7A1 high expression group (Fig.9.B). The results of immune 186 cell infiltration analysis showed that the expression of COL7A1 was significantly 187 negatively correlated with the infiltration of B cell, T cell CD8, Macrophage and DC in 188 LUSC, and the expression of COL7A1 was significantly negatively correlated with the 189 190 infiltration of B cell, T cell CD4, Macrophage and DC in HNSC (Fig.9.C).

191 Immunotherapy

Immunotherapy analysis from the TCIA database showed that the expression of
COL7A1 was not significantly correlated with IPS treated with CTLA4 (-) PD1 (-)
(Fig.10.A), and was significantly negatively correlated with IPS treated with CTLA4
(-) PD1 (+), CTLA4 (+) PD1 (-) and CTLA4 (+) PD1 (+) in LUSC (Fig.10.B-D). There
was no significant correlation between IPS receiving CTLA4 (-) PD1 (-), CTLA4 (-)
PD1 (+), CTLA4 (+) PD1 (-) and CTLA4 (+) PD1 (+) treatment in HNSC (Fig.10.E-

198 H).

199 **Discussion**

Even though multiple genes (COL7A1, HJURP, KIF18B and TMEM132A) with high accuracy in the training set were calculated by LASSO regression and SVM-RFE algorithm, only COL7A1 showed high accuracy in the validation set (AUC: 0.907). In specific cancer types, COL7A1 has poor prediction performance in ESCA samples in

204 the training set and CESC samples in the validation set. However, COL7A1 has high

accuracy in the diagnosis of HNSC and LUSC. Whether in the training set or the 205 validation set, COL7A1 has the potential to be used as a diagnostic marker for HNSC 206 and LUSC. The results showed that COL7A1 was worth exploring as a diagnostic 207 marker for LUSC (AUC in the training set was 0.987 and AUC in the validation set was 208 1). COL7A1 encodes collagen VII (C1), which is involved in the assembly of anchoring 209 fibrils that fix the epidermis and dermis²⁹. Previous studies have shown that alteration 210 of COL7A1 can cause Recessive dystrophic epidermolysis bullosa (RDEB), and RDEB 211 can cause skin fragility and persistent blisters, and can rapidly progress to fibrosis and 212 even SCCs^{29, 30}. Compared with normal esophageal tissue, COL7A1 is highly expressed 213 in ESCA.COL7A1 is significantly correlated with depth of tumor invasion and 214 lymphatic invasion in ESCA, and the expression of COL7A1 is significantly negatively 215 correlated with the 0-year survival rate of ESCA patients³¹. Although there was no 216 significant correlation between the expression of COL7A1 and the age, gender and 217 218 stage of patients including LUSC and HNSC patients, the results of prognostic analysis showed that the high expression of COL7A1 was significantly associated with shorter 219 OS and DSS in HNSC and LUSC patients, indicating that COL7A1 also has the 220 potential as a prognostic marker. In LUSC, the expression of COL7A1 was significantly 221 222 negatively correlated with StromalScore, ImmuneScore and ESTIMATEScore, as well as the infiltration of B cell, T cell CD8, Macrophage and DC, indicating that COL7A1 223 224 affects the tumor microenvironment and tumor immunity of LUSC. Further immunotherapy analysis showed that the expression of COL7A1 was significantly 225 negatively correlated with IPS in LUSC patients treated with CTLA4 (-) PD1 (+), 226 CTLA4 (+) PD1 (-) and CTLA4 (+) PD1 (+), indicating that COL7A1 may also have 227 228 the prospect of predicting the efficacy of LUSC immunotherapy.

Due to the unpredictability of the results of machine learning algorithms, our study has not yet obtained appropriate clinical tissues to verify its predictive performance as a diagnostic marker. However, our study includes different databases and data sets. The results of statistical calculations on the differential expression of COL7A1 in these cancer tissues and adjacent tissues are surprising, which provides a promising marker for the early diagnosis of LUSC and HNSC.

235 Conclusion

236 COL7A1 has the potential to be a diagnostic marker for LUSC and HNSC (especially

in LUSC). The high expression of COL7A1 is significantly correlated with shorter OS

238 in HNSC patients and LUSC patients and is significantly negatively correlated with IPS

- 239 in LUSC patients receiving CTLA4 (-) PD1 (+), CTLA4 (+) PD1 (-) and CTLA4 (+)
- 240 PD1 (+) immunotherapy.
- 241 **Declarations**
- 242 Ethics approval and consent to participate
- 243 Not applicable
- 244 **Consent for publication**
- 245 Not applicable

246 Availability of data and materials

247 The datasets analyzed during the current study are available in TCGA

248 (https://portal.gdc.cancer.gov/), GEO database (https://www.ncbi.nlm.nih.gov/geo/),

249 TISIDB database (<u>http://cis.hku.hk/TISIDB/</u>) and TCIA database (<u>https://tcia.at/home</u>).

250 **Competing interests**

- 251 The authors declare that they have no conflicts of interest to report regarding the present 252 study.
- 253 Funding
- 254 Not applicable

Author Contributions: Xianglai Jiang and Chenyu Wang conceived the study, Yongxin Ma comprehensively collected relevant data, Chenyu Wang completed the work on data analysis, Xianglai Jiang completed the draft, Jiaojiao Qi and Xianglai

- 258 Jiang reviewed the paper.
- 259 Acknowledgement
- 260 This work has benefited from the aforementioned databases.

261 **Reference**

Johnson, D. E.; Burtness, B.; Leemans, C. R.; Lui, V. W. Y.; Bauman, J. E.; Grandis, J. R.,
 Head and neck squamous cell carcinoma. *Nat Rev Dis Primers* **2020**, *6* (1), 92.

Kallini, J. R.; Hamed, N.; Khachemoune, A., Squamous cell carcinoma of the skin:
 epidemiology, classification, management, and novel trends. *Int J Dermatol* **2015**, *54* (2), 130-40.
 Small, W., Jr.; Bacon, M. A.; Bajaj, A.; Chuang, L. T.; Fisher, B. J.; Harkenrider, M. M.;

267 Jhingran, A.; Kitchener, H. C.; Mileshkin, L. R.; Viswanathan, A. N.; Gaffney, D. K., Cervical
268 cancer: A global health crisis. *Cancer* 2017, *123* (13), 2404-2412.

- Codipilly, D. C.; Wang, K. K., Squamous Cell Carcinoma of the Esophagus. *Gastroenterol Clin North Am* 2022, *51* (3), 457-484.
- Wei, K. X.; Hoang, L. N., Squamous and Glandular Lesions of the Vulva and Vagina: What's
 New and What Remains Unanswered? *Surg Pathol Clin* **2022**, *15* (2), 389-405.
- 273 6. Lau, S. C. M.; Pan, Y.; Velcheti, V.; Wong, K. K., Squamous cell lung cancer: Current
 274 landscape and future therapeutic options. *Cancer Cell* **2022**, *40* (11), 1279-1293.
- 275 7. Waldman, A.; Schmults, C., Cutaneous Squamous Cell Carcinoma. *Hematol Oncol Clin North*276 *Am* 2019, *33* (1), 1-12.

277 8. Derman, B. A.; Mileham, K. F.; Bonomi, P. D.; Batus, M.; Fidler, M. J., Treatment of
278 advanced squamous cell carcinoma of the lung: a review. *Translational lung cancer research* 2015,
279 4 (5), 524.

- Blobel, G. A.; Moll, R.; Franke, W. W.; Vogt-Moykopf, I., Cytokeratins in normal lung and
 lung carcinomas: I. Adenocarcinomas, squamous cell carcinomas and cultured cell lines. *Virchows Archiv B* 1984, *45*, 407-429.
- 10. Marur, S.; Forastiere, A. A. In *Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment*, Mayo Clinic Proceedings, Elsevier: 2016; pp 386-396.
- 285 11. Abnet, C. C.; Arnold, M.; Wei, W.-Q., Epidemiology of esophageal squamous cell carcinoma.
 286 *Gastroenterology* 2018, *154* (2), 360-373.
- 12. Ohashi, S.; Miyamoto, S. i.; Kikuchi, O.; Goto, T.; Amanuma, Y.; Muto, M., Recent
 advances from basic and clinical studies of esophageal squamous cell carcinoma. *Gastroenterology* 2015, *149* (7), 1700-1715.
- 13. Nicol, A. F.; de Andrade, C. V.; Brusadelli, M. G.; Lodin, H. M.; Wells, S. I.; Nuovo, G. J.,
 The distribution of novel biomarkers in carcinoma-in-situ, microinvasive, and squamous cell
 carcinoma of the uterine cervix. *Annals of Diagnostic Pathology* **2019**, *38*, 115-122.
- 293 14. Comprehensive genomic characterization of head and neck squamous cell carcinomas.
 294 *Nature* 2015, *517* (7536), 576-82.
- 15. Lin, D. C.; Hao, J. J.; Nagata, Y.; Xu, L.; Shang, L.; Meng, X.; Sato, Y.; Okuno, Y.;
 Varela, A. M.; Ding, L. W.; Garg, M.; Liu, L. Z.; Yang, H.; Yin, D.; Shi, Z. Z.; Jiang, Y. Y.;
 Gu, W. Y.; Gong, T.; Zhang, Y.; Xu, X.; Kalid, O.; Shacham, S.; Ogawa, S.; Wang, M. R.;
 Koeffler, H. P., Genomic and molecular characterization of esophageal squamous cell carcinoma. *Nat Genet* 2014, *46* (5), 467-73.
- 300 16. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012, *489*301 (7417), 519-25.
- 302 17. Fukusumi, T.; Califano, J. A., The NOTCH Pathway in Head and Neck Squamous Cell
 303 Carcinoma. *J Dent Res* 2018, *97* (6), 645-653.
- 18. Mori, T., Involvement of the p53-p16/RB pathway control mechanism in early-stage carcinogenesis in head and neck squamous cell carcinoma. *Pathol Int* **2022**, *72* (12), 577-588.
- 306 19. Shi, W.; Lee, K. E.; Wahba, G. In *Detecting disease-causing genes by LASSO-Patternsearch* 307 *algorithm*, BMC proceedings, BioMed Central: 2007; pp 1-5.
- 308 20. Sanz, H.; Valim, C.; Vegas, E.; Oller, J. M.; Reverter, F., SVM-RFE: selection and
 309 visualization of the most relevant features through non-linear kernels. *BMC bioinformatics* 2018,
 310 19 (1), 1-18.
- Zou, H., The adaptive lasso and its oracle properties. *Journal of the American statistical association* **2006**, *101* (476), 1418-1429.
- 22. Hou, J.; Aerts, J.; den Hamer, B.; van ljcken, W.; den Bakker, M.; Riegman, P.; van der
 Leest, C.; van der Spek, P.; Foekens, J. A.; Hoogsteden, H. C.; Grosveld, F.; Philipsen, S., Gene
 expression-based classification of non-small cell lung carcinomas and survival prediction. *PLoS One* 2010, *5* (4), e10312.
- Scotto, L.; Narayan, G.; Nandula, S. V.; Arias-Pulido, H.; Subramaniyam, S.; Schneider,
 A.; Kaufmann, A. M.; Wright, J. D.; Pothuri, B.; Mansukhani, M.; Murty, V. V., Identification of
 copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic
 approach in cervical cancer: potential role in progression. *Genes Chromosomes Cancer* 2008, *47*

- 321 (9), 755-65.
- 24. Hyland, P. L.; Zhang, H.; Yang, Q.; Yang, H. H.; Hu, N.; Lin, S. W.; Su, H.; Wang, L.;
 Wang, C.; Ding, T.; Fan, J. H.; Qiao, Y. L.; Sung, H.; Wheeler, W.; Giffen, C.; Burdett, L.;
 Wang, Z.; Lee, M. P.; Chanock, S. J.; Dawsey, S. M.; Freedman, N. D.; Abnet, C. C.;
 Goldstein, A. M.; Yu, K.; Taylor, P. R., Pathway, in silico and tissue-specific expression quantitative
 analyses of oesophageal squamous cell carcinoma genome-wide association studies data. *Int J Epidemiol* **2016**, *45* (1), 206-20.
- 25. Chen, C.; Méndez, E.; Houck, J.; Fan, W.; Lohavanichbutr, P.; Doody, D.; Yueh, B.;
 Futran, N. D.; Upton, M.; Farwell, D. G.; Schwartz, S. M.; Zhao, L. P., Gene expression profiling
 identifies genes predictive of oral squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev*2008, *17* (8), 2152-62.
- 332 26. Tompkins, J. D., Discovering DNA Methylation, the History and Future of the Writing on DNA.
 333 *J Hist Biol* **2022**, *55* (4), 865-887.
- 27. Dai, X.; Ren, T.; Zhang, Y.; Nan, N., Methylation multiplicity and its clinical values in cancer.
 Expert Rev Mol Med 2021, *23*, e2.
- 28. Legrand, O.; Perrot, J.-Y.; Baudard, M.; Cordier, A.; Lautier, R. g.; Simonin, G.;
 Zittoun, R.; Casadevall, N.; Marie, J.-P., The immunophenotype of 177 adults with acute myeloid
 leukemia: proposal of a prognostic score. *Blood, The Journal of the American Society of Hematology* 2000, *96* (3), 870-877.
- 340 29. Bolton, L., New options to manage epidermolysis bullosa. *Wounds* **2022**, *34* (12), 297-299.
- 30. Pfendner, E. G.; Lucky, A. W., Dystrophic Epidermolysis Bullosa. In *GeneReviews(®)*, Adam, M.
- P.; Mirzaa, G. M.; Pagon, R. A.; Wallace, S. E.; Bean, L. J. H.; Gripp, K. W.; Amemiya, A., Eds.
 University of Washington, Seattle
- Copyright © 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark
 of the University of Washington, Seattle. All rights reserved.: Seattle (WA), 1993.
- 346 31. Kita, Y.; Mimori, K.; Tanaka, F.; Matsumoto, T.; Haraguchi, N.; Ishikawa, K.;
 347 Matsuzaki, S.; Fukuyoshi, Y.; Inoue, H.; Natsugoe, S., Clinical significance of LAMB3 and COL7A1
 348 mRNA in esophageal squamous cell carcinoma. *European Journal of Surgical Oncology (EJSO)*349 **2009**, *35* (1), 52-58.
- 350

351 Figure 1: LASSO regression (A) and SVM-RFE (B) calculation results.



353

Figure 2: ROC curves of CHI3L2 (A), COL7A1 (B), CRNN (C), GPIHBP1 (D),

HJURP (E), IL33 (F), KIF18B (G), SPP1 (H), TMEM132A (I) and VEGFD (J) in the diagnosis of SCCs in TCGA database.



357 358

Figure 3: ROC curves of COL7A1 (A), HJURP (B), KIF18B (C) and TMEM132A
(D) in the diagnosis of SCCs in GEO database.



361 362

363 Figure 4: The ROC curves of COL7A1 in the diagnosis of CESC (A), ESCA (B),

HNSC (C) and LUSC (D) in TCGA database; the ROC curve of COL7A1 in the diagnosis of CESC (E), ESCA (F), HNSC (G) and LUSC (H) in GEO database.



367

Figure 5: The correlation between COL7A1 expression and age (A), gender (B), stage 368 (C), T stage (D), N stage (E) and M stage (F). 369



370 371

Figure 6: The correlation between the expression of COL7A1 and OS (A), DSS (B), 372

DFI (C), PFI (D) in LUSC patients; the correlation between COL7A1 expression and 373 OS (E), DSS (F), DFI (G), PFI (H) in HNSC patients. 374



Figure 7: The difference of COL7A1 promoter methylation level between LUSC 377

samples and adjacent samples (A); the difference of COL7A1 promoter methylation level between LUSC samples and adjacent samples (B).



380

381

- 382 Figure 8: GO enrichment analysis (A) and KEGG enrichment (B) of COL7A1 in
- 383 LUSC based on GESA; GO enrichment analysis (C) and KEGG enrichment (D) of
- 384 COL7A1 in HNSC based on GESA.



385 386

Figure 9: The correlation between the expression of COL7A1 and the tumor

- 388 microenvironment score in LUSC (A) ; the correlation between the expression of
- 389 COL7A1 and the tumor microenvironment score in HNSC (B) ; the correlation
- 390 between COL7A1 expression and immune cell infiltration (C).



391



Figure 10: The correlation between COL7A1 expression and IPS in LUSC patients treated with CTLA4 (-) PD1 (-), CTLA4 (-) PD1 (+), CTLA4 (+) PD1 (-) and CTLA4

(+) PD1 (+) (A-D); the correlation between COL7A1 expression and IPS in HNSC
patients receiving CTLA4 (-) PD1 (-), CTLA4 (-) PD1 (+), CTLA4 (+) PD1 (-) and



